Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes.

Blood Adv 2022 Sep 13

Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes.

Related Questions

How do you approach treatment for a fit patient with unmutated CLL who has progressed after BTKi and venetoclax containing regimens in the first and second line?